Human beta cell

Human beta cells are specialized endocrine cells located in the pancreatic islets that play a critical role in maintaining blood glucose homeostasis by secreting insulin in response to increased blood glucose levels[5][6][1]. Therapeutic approaches involving the implantation of human beta cells—often derived from stem cells or donor tissue—aim to restore physiologic insulin secretion for patients with diabetes, especially type 1 diabetes where endogenous beta cells are destroyed[2][3][5]. Implanted beta cells can reestablish glucose-responsive insulin release, with C-peptide measurement used as a biomarker for function and maturation. Challenges for cell therapy include immune rejection, the need for vascularization, potential for teratoma formation, and achieving mature, glucose-responsive beta cell populations capable of long-term function[2][3][5]. Drugs such as sulfonylureas, GLP-1 receptor agonists, and DYRK1A inhibitors, as well as small molecules like WS6, influence beta cell function or proliferation[4][5]. While the concept enables physiologic glycemic regulation, "physiologic regulation via implanted human beta cells" is not a molecular target but rather refers to a therapeutic strategy utilizing beta cells as the functional unit. Key clarification: There is no canonical protein, molecular target, or receptor named "Physiologic regulation via implanted human beta cells." The entry refers to a cell-based therapy rather than a discrete molecule, so it is not considered a valid therapeutic target according to standard molecular taxonomy[5][2][1].

Other names

Pancreatic beta cellBeta cellHuman pancreatic beta cell

Stimulation of insulin secretion, Beta cell proliferation, Beta cell survival, Beta cell differentiation